Showing results (281-290 of 291) with videos related to
Sort By:
Pageof 30
Wellcome Open Research|December 28, 2021
Impact of COVID-19 on non-COVID intensive care unit service utilization, case mix and outcomes: A registry-based analysis from India, Neill Kj Adhikari, Abi Beane, et al.Journal of the National Cancer Institute. Monographs|November 12, 2024
A prospective cohort study comparing efficacy of 1 dose of quadrivalent human papillomavirus vaccine to 2 and 3 doses at an average follow up of 12 years postvaccinationSylla G Malvi, Pulikkottil O Esmy, Richard Muwonge, et al.Human Vaccines & Immunotherapeutics|December 11, 2023
Impact of age at vaccination and cervical HPV infection status on binding and neutralizing antibody titers at 10 years after receiving single or higher doses of quadrivalent HPV vaccineNeerja Bhatla, Richard Muwonge, Sylla G Malvi, et al.Plos One|December 29, 2020
Acquisition, prevalence and clearance of type-specific human papillomavirus infections in young sexually active Indian women: A community-based multicentric cohort studyRichard Muwonge, Partha Basu, Tarik Gheit, et al.The Lancet. Oncology|October 11, 2021
Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort studyPartha Basu, Sylla G Malvi, Smita Joshi, et al.Vaccine|November 29, 2022
Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccinationSmita Joshi, Devasena Anantharaman, Richard Muwonge, et al.Papillomavirus Research (Amsterdam, Netherlands)|March 27, 2018
Are two doses of human papillomavirus vaccine sufficient for girls aged 15-18 years? Results from a cohort study in IndiaNeerja Bhatla, Bhagwan M Nene, Smita Joshi, et al.Wellcome Open Research|November 17, 2020
Implementing an intensive care registry in India: preliminary results of the case-mix program and an opportunity for quality improvement and researchNeill K J Adhikari, Rajeshwari Arali, Udara Attanayake, et al.Papillomavirus Research (Amsterdam, Netherlands)|February 4, 2019
Two-dose recommendation for Human Papillomavirus vaccine can be extended up to 18 years - updated evidence from Indian follow-up cohort studyPartha Basu, Richard Muwonge, Neerja Bhatla, et al.The Lancet. Oncology|December 15, 2015
Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort studyRengaswamy Sankaranarayanan, Priya Ramesh Prabhu, Michael Pawlita, et al.Pageof 30